Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - ELEC
LB  - 1.
AU  - National Institute for Health and Clinical Excellence
TI  - Guide to the single technology (STA) process
PY  - 2006
UR  - www.nice.org.uk/page.aspx?o=STAprocessguide
ER  - 
TY  - ELEC
LB  - 2.
AU  - Office for National Statistics
TI  - Breast cancer: incidence rises while deaths continue to fall
PY  - 2005
UR  - www.statistics.gov.uk/cci/nugget_print.asp?ID=575
M1  - 1 December 2005
ER  - 
TY  - ELEC
LB  - 3.
AU  - Office for National Statistics
TI  - Cancer statistics registrations: registrations of cancer diagnosed in 2004, England
PY  - 2007
UR  - www.statistics.gov.uk/statbase/Product.asp?vlnk=8843
M1  - 29 August 2007
ER  - 
TY  - ELEC
LB  - 4.
AU  - Welsh Cancer Intelligence and Surveillance Unit
TI  - Cancer incidence in Wales
PY  - 2007
UR  - www.wales.nhs.uk/sites3/page.cfm?orgid=242%26pid=21936
ER  - 
TY  - ELEC
LB  - 5.
AU  - Rachet, B
AU  - Coleman, M
AU  - Cooper, N
AU  - Quinn, M
AU  - Wood, H
TI  - Breast cancer survival, England and Wales, 1991– 2003. Predicted trends in long-term survival from breast cancer in women: age; and Government office region in England and Wales
PY  - 2006
UR  - www.statistics.gov.uk/statbase/ssdataset.asp?vlnk=9132%26More=Y
M1  - 1 December 2005
ER  - 
TY  - JOUR
LB  - 6.
AU  - Harris, JR
AU  - Lippman, ME
AU  - Veronesi, U
AU  - Willett, W
TI  - Breast cancer (2)
J2  - N Engl J Med
PY  - 1992
VL  - 327
SP  - 390
EP  - 398
ER  - 
TY  - JOUR
LB  - 7.
AU  - Penault-Llorca, F
AU  - Vincent-Salomon, A
AU  - Mathieu, M
AU  - Trillet-Lenoir, V
AU  - Khayat, D
AU  - Marty, M
TI  - Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC)
J2  - J Clin Oncol
PY  - 2005
VL  - 23
IS  - 16S
SP  - 764
ER  - 
TY  - JOUR
LB  - 8.
AU  - Geyer, CE
AU  - Forster, J
AU  - Lindquist, D
AU  - Chan, S
AU  - Romieu, CG
AU  - Pienkowski, T
TI  - Lapatinib plus capecitabine for HER2-positive advanced breast cancer [see comment]
J2  - N Engl J Med
PY  - 2006
VL  - 355
SP  - 2733
EP  - 2743
ER  - 
TY  - JOUR
LB  - 9.
AU  - Brown, RE
AU  - Hutton, J
TI  - Cost–utility model comparing docetaxel and paclitaxel in advanced breast cancer patients
J2  - Anticancer Drugs
PY  - 1998
VL  - 9
SP  - 899
EP  - 907
ER  - 
TY  - JOUR
LB  - 10.
AU  - Brown, RE
AU  - Hutton, J
AU  - Burrell, A
TI  - Cost effectiveness of treatment options in advanced breast cancer in the UK
J2  - Pharmacoeconomics
PY  - 2001
VL  - 19
SP  - 1091
EP  - 1102
ER  - 
TY  - JOUR
LB  - 11.
AU  - Cooper, NJ
AU  - Abrams, KR
AU  - Sutton, AJ
AU  - Turner, D
AU  - Lambert, PC
TI  - A Bayesian approach to Markov modelling in cost-effectiveness analyses: application to taxane use in advanced breast cancer
J2  - J R Stat Soc Sers A Stat Soc
PY  - 2003
VL  - 166
SP  - 389
EP  - 405
ER  - 
TY  - JOUR
LB  - 12.
AU  - Hutton, J
AU  - Brown, R
AU  - Borowitz, M
AU  - Abrams, K
AU  - Rothman, M
AU  - Shakespeare, A
TI  - A new decision model for cost–utility comparisons of chemotherapy in recurrent metastatic breast cancer
J2  - Pharmacoeconomics
PY  - 1996
VL  - 9
IS  - Suppl. 2
SP  - 8
EP  - 22
ER  - 
TY  - JOUR
LB  - 13.
AU  - Launois, R
AU  - Reboul-Marty, J
AU  - Henry, B
AU  - Bonneterre, J
TI  - A cost–utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine
J2  - Pharmacoeconomics
PY  - 1996
VL  - 10
SP  - 504
EP  - 521
ER  - 
TY  - JOUR
LB  - 14.
AU  - Lloyd, A
AU  - Nafees, B
AU  - Narewska, J
AU  - Dewilde, S
AU  - Watkins, J
TI  - Health state utilities for metastatic breast cancer
J2  - Br J Cancer
PY  - 2006
VL  - 95
SP  - 683
EP  - 690
ER  - 
TY  - JOUR
LB  - 15.
AU  - Glenny, A
AU  - Altman, D
AU  - Song, F
AU  - Sakarovitch, C
AU  - Deeks, J
AU  - D’Amico, R
TI  - Indirect comparisons of competing interventions
J2  - Health Technol Assess
PY  - 2005
VL  - 9
IS  - 26
ER  -